Lercanidipine Eg

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Eg, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering systemic vascular resistance.

GNH USA supplies Lercanidipine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used to manage high‑blood‑pressure disorders. - Essential hypertension: reduces both systolic and diastolic blood pressure. - Isolated systolic hypertension: improves arterial compliance and lowers systolic pressure. - Secondary hypertension (e.g., renovascular): assists in blood‑pressure control when combined with other antihypertensives.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: especially on standing. - Tachycardia: increased heart rate. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: angioedema, rash, or anaphylaxis. - Arrhythmias: abnormal heart rhythms. - Heart block: conduction disturbances.

Before prescribing Lercanidipine, clinicians should consider several safety factors. - Blood pressure monitoring: check baseline and periodic readings. - Cardiovascular disease: use cautiously in severe aortic stenosis or heart failure. - Liver impairment: dose adjustment may be needed. - Elderly patients: initiate at the lowest effective dose. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lercanidipine may interact with other medicines that affect its metabolism or hemodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise plasma concentrations. - Grapefruit juice: may increase drug exposure. - Co‑administration with other calcium‑channel blockers: risk of additive hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, requiring BP monitoring. - Beta‑blockers: combined use can cause excessive bradycardia. - ACE inhibitors or ARBs: monitor renal function and potassium levels.